

1 XAVIER BECERRA  
Attorney General of California  
2 JANE ZACK SIMON  
Supervising Deputy Attorney General  
3 LYNNE K. DOMBROWSKI  
Deputy Attorney General  
4 State Bar No. 128080  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3439  
6 Facsimile: (415) 703-5480  
E-mail: Lynne.Dombrowski@doj.ca.gov  
7 *Attorneys for Complainant*

FILED  
STATE OF CALIFORNIA  
MEDICAL BOARD OF CALIFORNIA  
SACRAMENTO  
BY: *[Signature]* April 25 2018  
ANALYST

8 **BEFORE THE**  
9 **MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
11 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation/Petition to  
12 Revoke Probation Against:

13 **ERIC DAVID GORDON, M.D.**  
14 3471 Regional Parkway  
Santa Rosa CA 95403-1202

15 Physician's and Surgeon's Certificate  
No. G 82342,

16 Respondent.

Case No. 800-2018-039973

**ACCUSATION AND PETITION TO  
REVOKE PROBATION**

18 Complainant alleges:

19 **PARTIES**

20 1. Kimberly Kirchmeyer (Complainant) brings this Accusation and Petition to Revoke  
21 Probation (hereinafter "Accusation") solely in her official capacity as the Executive Director of  
22 the Medical Board of California, Department of Consumer Affairs ("Board" or "Medical Board").

23 2. On or about July 17, 1996, the Medical Board issued Physician's and Surgeon's  
24 Certificate Number G 82342 to Eric David Gordon, M.D. (Respondent). The Physician's and  
25 Surgeon's Certificate will expire on January 31, 2020, unless renewed. Respondent's license  
26 certificate is presently subject to disciplinary action through a probation of three years with  
27 special terms and conditions, as presented in more detail in paragraph 3.

28 ///





1           10. Section 2227 of the Code states:

2           “(a) A licensee whose matter has been heard by an administrative law judge of the Medical  
3 Quality Hearing Panel as designated in Section 11371 of the Government Code, or whose default  
4 has been entered, and who is found guilty, or who has entered into a stipulation for disciplinary  
5 action with the board, may, in accordance with the provisions of this chapter:

6           “(1) Have his or her license revoked upon order of the board.

7           “(2) Have his or her right to practice suspended for a period not to exceed one year upon  
8 order of the board.

9           “(3) Be placed on probation and be required to pay the costs of probation monitoring upon  
10 order of the board.

11           “(4) Be publicly reprimanded by the board. The public reprimand may include a  
12 requirement that the licensee complete relevant educational courses approved by the board.

13           “(5) Have any other action taken in relation to discipline as part of an order of probation, as  
14 the board or an administrative law judge may deem proper.

15           “(b) Any matter heard pursuant to subdivision (a), except for warning letters, medical  
16 review or advisory conferences, professional competency examinations, continuing education  
17 activities, and cost reimbursement associated therewith that are agreed to with the board and  
18 successfully completed by the licensee, or other matters made confidential or privileged by  
19 existing law, is deemed public, and shall be made available to the public by the board pursuant to  
20 Section 803.1.”

21           11. Section 2228 of the Code states:

22           “The authority of the board or the California Board of Podiatric Medicine to discipline a  
23 licensee by placing him or her on probation includes, but is not limited to, the following:

24           “(a) Requiring the licensee to obtain additional professional training and to pass an  
25 examination upon the completion of the training. The examination may be written or oral, or both,  
26 and may be a practical or clinical examination, or both, at the option of the board or the  
27 administrative law judge.

28           ///

1           “(b) Requiring the licensee to submit to a complete diagnostic examination by one or more  
2 physicians and surgeons appointed by the board. If an examination is ordered, the board shall  
3 receive and consider any other report of a complete diagnostic examination given by one or more  
4 physicians and surgeons of the licensee's choice.

5           “(c) Restricting or limiting the extent, scope, or type of practice of the licensee, including  
6 requiring notice to applicable patients that the licensee is unable to perform the indicated  
7 treatment, where appropriate.

8           “(d) Providing the option of alternative community service in cases other than violations  
9 relating to quality of care.

10           12.       Section 2234 of the Code, states:

11           “The board shall take action against any licensee who is charged with unprofessional  
12 conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not  
13 limited to, the following:

14           “(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the  
15 violation of, or conspiring to violate any provision of this chapter.

16           “(b) Gross negligence.

17           “(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or  
18 omissions. An initial negligent act or omission followed by a separate and distinct departure from  
19 the applicable standard of care shall constitute repeated negligent acts.

20           “(1) An initial negligent diagnosis followed by an act or omission medically appropriate  
21 for that negligent diagnosis of the patient shall constitute a single negligent act.

22           “(2) When the standard of care requires a change in the diagnosis, act, or omission that  
23 constitutes the negligent act described in paragraph (1), including, but not limited to, a  
24 reevaluation of the diagnosis or a change in treatment, and the licensee's conduct departs from the  
25 applicable standard of care, each departure constitutes a separate and distinct breach of the  
26 standard of care.

27           “(d) Incompetence.

28       ///

1           “(e) The commission of any act involving dishonesty or corruption which is substantially  
2 related to the qualifications, functions, or duties of a physician and surgeon.

3           “(f) Any action or conduct which would have warranted the denial of a certificate.

4           “(g) The practice of medicine from this state into another state or country without meeting  
5 the legal requirements of that state or country for the practice of medicine. Section 2314 shall not  
6 apply to this subdivision. This subdivision shall become operative upon the implementation of the  
7 proposed registration program described in Section 2052.5.

8           “(h) The repeated failure by a certificate holder, in the absence of good cause, to attend and  
9 participate in an interview by the board. This subdivision shall only apply to a certificate holder  
10 who is the subject of an investigation by the board.”

11           13. Section 2242 of the Code states:

12           “(a) Prescribing, dispensing, or furnishing dangerous drugs as defined in Section 4022  
13 without an appropriate prior examination and a medical indication, constitutes unprofessional  
14 conduct.

15           “(b) No licensee shall be found to have committed unprofessional conduct within the  
16 meaning of this section if, at the time the drugs were prescribed, dispensed, or furnished, any of  
17 the following applies:

18           “(1) The licensee was a designated physician and surgeon or podiatrist serving in the  
19 absence of the patient's physician and surgeon or podiatrist, as the case may be, and if the drugs  
20 were prescribed, dispensed, or furnished only as necessary to maintain the patient until the return  
21 of his or her practitioner, but in any case no longer than 72 hours.

22           “(2) The licensee transmitted the order for the drugs to a registered nurse or to a  
23 licensed vocational nurse in an inpatient facility, and if both of the following conditions exist:

24           “(A) The practitioner had consulted with the registered nurse or licensed vocational  
25 nurse who had reviewed the patient's records.

26           “(B) The practitioner was designated as the practitioner to serve in the absence of the  
27 patient's physician and surgeon or podiatrist, as the case may be.

28           ///



1 many concerning issues with Respondent's practice pattern in pain management and deemed  
2 some of the practice patterns as "Unsafe – Does not meet standard of care."

3 18. For the time period of March through May 2017, the Practice Monitor identified the  
4 following departures from the standards of care and of practice by Respondent:

5 a. Respondent's chart notes were not in standard SOAP format and most notes did not  
6 mention any chief complaints of the patients.

7 b. Respondent's subjective findings in the chart notes were too broad, without any  
8 specific and detailed information about the patients' individual pain complaints.

9 c. Respondent failed to document adequate information about the patients' past pain  
10 therapy, current doses of medications, and their side effects and efficacy.

11 d. The physical exam findings were too brief and non-specific for the presented clinical  
12 problems.

13 e. Respondent administered intravenous narcotics and sedatives to his patients as an  
14 outpatient practice without documentation of a reasonable clinical justification and without  
15 having proper training in conscious sedation.

16 f. Respondent prescribed narcotic medication to a patient who is currently using  
17 cannabis without documenting an adequate risk assessment and sound clinical justification.

18 g. Respondent's pain assessments of his patients were inadequate and poorly supported  
19 by non-specific subjective and objective findings.

20 h. Respondent failed to consult with and/or co-manage with mental health professionals  
21 the care of his patients with significant co-morbid psychological conditions.

22 19. Respondent was aware of the Practice Monitor's evaluation and the noted deficiencies  
23 that were found in Respondent's practice that needed to be improved to comply with the standard  
24 of the medical community.

25 20. On September 28, 2017, the Practice Monitor visited Respondent's office practice in  
26 Santa Rosa. In a report dated October 4, 2017, the Practice Monitor summarized his observations  
27 and assessments of Respondent's practice as a result of his on-site review:  
28



1 a. Respondent has an IV-medication infusion practice whereby chronic pain patients are  
2 periodically infused with controlled substances, e.g. a narcotic (fentanyl), with anxiolytics  
3 (Versed, Xanax), and/or with an anesthetic sedative (ketamine), which practice is outside the  
4 boundaries of the standard of care and should be stopped immediately.

5 b. Respondent lacked knowledge about the current definition of "conscious sedation"  
6 and the requirements associated with his practice of regular outpatient IV infusions of narcotics  
7 and anxiolytics.

8 c. Respondent did not have a current certification for Advanced Cardiac Life Support  
9 (ACLS), although he was the only physician at his clinic facility where patients were routinely  
10 provided IV medication infusions that often involved risks related to conscious sedation, such as  
11 respiratory or cardiac arrest.

12 d. Respondent's practice was not in compliance with basic standards of practice  
13 involving the proper management of on-site medications and the availability of proper  
14 resuscitation equipment in case of an emergency. For example, some of the medications in the  
15 ACLS kits were expired and there was only one size of ventilation mask, no larynxscopes or  
16 endotracheal tubes.

17 e. Respondent was not in compliance with the standards of practice because he did not  
18 have proper written policies and protocols for: 1) the evaluating of a patient pre- and post-  
19 infusion; 2) the proper handling of a medical emergency; 3) the proper labeling and storing of  
20 controlled substance and IV-medications, particularly of multi-dosing vials.

21 f. Respondent was unable to provide his Practice Monitor with a complete chart to  
22 review for any of his patients, although he had been given advance notice that the Practice  
23 Monitor wanted to review a complete chart where Respondent had performed and documented an  
24 initial evaluation, medical history, and physical examination of a patient.

25 g. Dr. Gordon's evaluation of three patients, who all have chronic pain problems and at  
26 least one who was on a very high narcotic regimen for many years, was too general and lacked  
27 specificity in formulating a diagnosis. Respondent also failed to recognize that one patient's  
28 development of clonus, which are muscular spasms with repeated rhythmic contractions, was very

1 likely a side effect from the long-term usage of high doses of opioids that Respondent was  
2 prescribing.

3 h. Respondent lacked knowledge about some very basic clinical skills to use in  
4 evaluating, examining, and treating patients with chronic pain, skills that any physician who is  
5 managing chronic pain patients is expected to know and practice.

6 21. On or about September 28, 2017, at the conclusion of his site visit, the Practice  
7 Monitor discussed with Respondent his concerns about the observed deficiencies in the practice  
8 and his recommendations to conform his practice of managing chronic pain patients to the  
9 medical community's standards of care and practice.

10 22. In his second quarterly report regarding Respondent's practice, dated October 5, 2017,  
11 the Practice Monitor summarized his monthly evaluations of Respondent's pain management  
12 charts for the period from June through August, 2017. The Practice Monitor found no significant  
13 improvement in the deficiencies identified in the first quarterly assessment and concluded that:  
14 "Overall, I found no major improvement in the participant's [Respondent's] practice pattern in  
15 pain management. Some of practice patterns are deemed Unsafe – Does not meet standard of  
16 care."

17 23. In the third quarterly report regarding Respondent's practice, dated January 18, 2018,  
18 the Practice Monitor summarized his monthly evaluations of Respondent's pain management  
19 charts for the period from September through November, 2017. Although the Practice Monitor  
20 found some small improvement in some of Respondent's patient chart documentation, the overall  
21 score for documentation was at the "Low Satisfactory level" for the 18-20 charted patient visits/  
22 procedures that were reviewed. The Practice Monitor's evaluation concluded that some of  
23 Respondent's practice patterns continue to be deemed as "Unsafe – Does not meet standard of  
24 care."

25 24. For the time period of September through November, 2017, the Practice Monitor  
26 identified the following departures from the standards of care and of practice by Respondent:

27 a. Overall, Respondent's documented pain assessments were poorly supported by non-  
28 specific subjective and objective findings. Respondent's patient records are confusing and not

1 well-structured, with information put in the wrong place, e.g. a phone record included a  
2 description of a physical exam, and procedure notes were bundled in with regular clinic visit  
3 notes. Respondent's records lack any clear description of the informed consent, the medical  
4 indication for the procedure, and the required details of the procedure. Respondent's chart notes  
5 are too brief and non-specific as to the physical examination findings related to the presented  
6 clinical problems. Some of the notes of follow-up visits failed to document any examination  
7 findings.

8       b. A majority of Respondent's patients have been diagnosed with Lyme Disease and  
9 Respondent presumes that all pain presentations of these patients, including ongoing neurological  
10 manifestations such as seizures, are a manifestation of Lyme Disease. Respondent, therefore,  
11 does not perform any additional assessments, such as a more detailed workup or a neurology  
12 consult, to ascertain other possible causes of their pain, which might be treatable and reversible.

13       c. Respondent continues to treat patients with chronic pain and headaches with long-  
14 term use of IM Demerol or other IV opioids without documented medical indications to support  
15 the treatments. Such treatments have the potential to impose a negative impact on the patient's  
16 pain management and inadvertently increase the practice risks. Opioids can, in some patients,  
17 make the headache pain worse if administered too frequently, on a chronic basis.

18       d. Respondent demonstrated a lack of knowledge about the standard of care by  
19 considering the use of Percedex, an anesthesia sedation agent that is mainly used in intra-  
20 operative and intensive care settings, to treat a patient who had anxiety and mood issues.  
21 Respondent considered providing the Percedex as an outpatient IV-infusion regimen, which is  
22 clearly outside the standard of care. There was no documented medical indication or justification  
23 for the treatment and Respondent did not seek input from any mental health professionals.

24       25. In all three of his written quarterly reviews and in his written report of his on-site  
25 review of Respondent's practice, the Practice Monitor has concluded that Respondent's practice is  
26 unsafe and outside the standards of care and that Respondent has not made the necessary  
27 improvements to his prescribing and pain management practices to be in compliance with the  
28 medical community's standards.






## Exhibit A

BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

In the Matter of the Accusation )  
Against: )  
)  
)  
ERIC DAVID GORDON, M.D. )  
)  
Physician's and Surgeon's )  
Certificate No. G82342 )  
)  
Respondent )  
\_\_\_\_\_ )

Case No. 12-2012-227503

MEDICAL BOARD OF CALIFORNIA  
I do hereby certify that this document is a true  
and correct copy of the original on file in this  
office.  
  
\_\_\_\_\_  
Signature  
For Custodian of Records  
\_\_\_\_\_  
Title  
1/8/18  
\_\_\_\_\_  
Date


DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on December 16, 2016.

IT IS SO ORDERED: November 18, 2016.

MEDICAL BOARD OF CALIFORNIA



\_\_\_\_\_  
Jamie Wright, J.D.  
Chair, Panel A

1 KAMALA D. HARRIS  
Attorney General of California  
2 JANE ZACK SIMON  
Supervising Deputy Attorney General  
3 LYNNE DOMBROWSKI (State Bar No. 128080)  
Deputy Attorney General  
4 CAROLYNE EVANS (State Bar No. 289206)  
Deputy Attorney General  
5 455 Golden Gate Avenue, Suite 11000  
San Francisco, CA 94102-7004  
6 Telephone: (415) 703-5578 (Dombrowski)  
Telephone: (415) 703-1211 (Evans)  
7 Facsimile: (415) 703-5480  
*Attorneys for Complainant*

8  
9 **BEFORE THE**  
**MEDICAL BOARD OF CALIFORNIA**  
10 **DEPARTMENT OF CONSUMER AFFAIRS**  
**STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:

Case No. 12-2012-227503

12 **ERIC DAVID GORDON, M.D.**

OAH No. 2016060898

13 3471 Regional Parkway  
14 Santa Rosa CA 95403

**STIPULATED SETTLEMENT AND  
DISCIPLINARY ORDER**

15 Physician's and Surgeon's Certificate No.  
16 G82342

17 Respondent.

18  
19 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
20 entitled proceedings that the following matters are true:

21 PARTIES

22 1. Kimberly Kirchmeyer (Complainant) is the Executive Director of the Medical Board  
23 of California (Board). She brought this action solely in her official capacity and is represented in  
24 this matter by Kamala D. Harris, Attorney General of the State of California, by Lynne  
25 Dombrowski and by Carlyne Evans, Deputy Attorneys General.

26 2. Respondent Eric David Gordon, M.D. (Respondent) is represented in this proceeding  
27 by attorney Sharon Barclay Kime, whose address is Pacific West Law Group, LLP, Courthouse  
28 Square, 1000 Fourth Street, Suite 800, San Rafael, CA 94901.









1 cultivate marijuana for the personal medical purposes of the patient. Respondent shall fully  
2 document in the patient's chart that the patient or the patient's primary caregiver was so  
3 informed. Nothing in this condition prohibits Respondent from providing the patient or the  
4 patient's primary caregiver information about the possible medical benefits resulting from the  
5 use of marijuana.

6 2. CONTROLLED SUBSTANCES- MAINTAIN RECORDS AND ACCESS TO  
7 RECORDS AND INVENTORIES. Respondent shall maintain a record of all controlled

8 substances ordered, prescribed, dispensed, administered, or possessed by Respondent, and any  
9 recommendation or approval which enables a patient or patient's primary caregiver to possess or  
10 cultivate marijuana for the personal medical purposes of the patient within the meaning of Health  
11 and Safety Code section 11362.5, during probation, showing all the following: 1) the name and  
12 address of patient; 2) the date; 3) the character and quantity of controlled substances involved;  
13 and 4) the indications and diagnosis for which the controlled substances were furnished.

14 Respondent shall keep these records in a separate file or ledger, in chronological order. All  
15 records and any inventories of controlled substances shall be available for immediate inspection  
16 and copying on the premises by the Board or its designee at all times during business hours and  
17 shall be retained for the entire term of probation.

18 3. EDUCATION COURSE. Within 60 calendar days of the effective date of this  
19 Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee  
20 for its prior approval educational program(s) or course(s) which shall not be less than 40 hours  
21 per year, for each year of probation. The educational program(s) or course(s) shall be aimed at  
22 correcting any areas of deficient practice or knowledge and shall be Category I certified. At least  
23 20 hours of coursework annually shall pertain to the management of chronic pain. The  
24 educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to  
25 the Continuing Medical Education (CME) requirements for renewal of licensure. Following the  
26 completion of each course, the Board or its designee may administer an examination to test  
27 Respondent's knowledge of the course. Respondent shall provide proof of attendance for 65  
28 hours of CME of which 40 hours were in satisfaction of this condition.

1           4.    PRESCRIBING PRACTICES COURSE. Within 60 calendar days of the effective  
2 date of this Decision, Respondent shall enroll in a course in prescribing practices equivalent to the  
3 Prescribing Practices Course at the Physician Assessment and Clinical Education Program,  
4 University of California, San Diego School of Medicine (Program), approved in advance by the  
5 Board or its designee. Respondent shall provide the program with any information and documents  
6 that the Program may deem pertinent. Respondent shall participate in and successfully complete  
7 the classroom component of the course not later than six (6) months after Respondent's initial  
8 enrollment. Respondent shall successfully complete any other component of the course within  
9 one (1) year of enrollment. The prescribing practices course shall be at Respondent's expense  
10 and shall be in addition to the Continuing Medical Education (CME) requirements for renewal of  
11 licensure.

12           A prescribing practices course taken after the acts that gave rise to the charges in the  
13 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
14 or its designee, be accepted towards the fulfillment of this condition if the course would have  
15 been approved by the Board or its designee had the course been taken after the effective date of  
16 this Decision.

17           Respondent shall submit a certification of successful completion to the Board or its  
18 designee not later than 15 calendar days after successfully completing the course, or not later than  
19 15 calendar days after the effective date of the Decision, whichever is later.

20           5.    MEDICAL RECORD KEEPING COURSE. Within 60 calendar days of the effective  
21 date of this Decision, Respondent shall enroll in a course in medical record keeping equivalent to  
22 the Medical Record Keeping Course offered by the Physician Assessment and Clinical Education  
23 Program, University of California, San Diego School of Medicine (Program), approved in  
24 advance by the Board or its designee. Respondent shall provide the program with any information  
25 and documents that the Program may deem pertinent. Respondent shall participate in and  
26 successfully complete the classroom component of the course not later than six (6) months after  
27 Respondent's initial enrollment. Respondent shall successfully complete any other component of  
28 the course within one (1) year of enrollment. The medical record keeping course shall be at

1 Respondent's expense and shall be in addition to the Continuing Medical Education (CME)  
2 requirements for renewal of licensure.

3 A medical record keeping course taken after the acts that gave rise to the charges in the  
4 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the Board  
5 or its designee, be accepted towards the fulfillment of this condition if the course would have  
6 been approved by the Board or its designee had the course been taken after the effective date of  
7 this Decision.

8 Respondent shall submit a certification of successful completion to the Board or its  
9 designee not later than 15 calendar days after successfully completing the course, or not later than  
10 15 calendar days after the effective date of the Decision, whichever is later.

11 6. MONITORING - PRACTICE. Within 30 calendar days of the effective date of this  
12 Decision, Respondent shall submit to the Board or its designee for prior approval as a practice  
13 monitor, the name and qualifications of one or more licensed physicians and surgeons whose  
14 licenses are valid and in good standing, and who are certified in pain medicine by the American  
15 Board of Medical Specialties (ABMS). A monitor shall have no prior or current business or  
16 personal relationship with Respondent, or other relationship that could reasonably be expected to  
17 compromise the ability of the monitor to render fair and unbiased reports to the Board, including  
18 but not limited to any form of bartering, shall be in Respondent's field of practice, and must agree  
19 to serve as Respondent's monitor. Respondent shall pay all monitoring costs.

20 The Board or its designee shall provide the approved monitor with copies of the Decision  
21 and Accusation, and a proposed monitoring plan. Within 15 calendar days of receipt of the  
22 Decision, Accusation, and proposed monitoring plan, the monitor shall submit a signed statement  
23 that the monitor has read the Decision and Accusation, fully understands the role of a monitor,  
24 and agrees or disagrees with the proposed monitoring plan. If the monitor disagrees with the  
25 proposed monitoring plan, the monitor shall submit a revised monitoring plan with the signed  
26 statement for approval by the Board or its designee.

27 Within 60 calendar days of the effective date of this Decision, and continuing throughout  
28 probation, Respondent's practice shall be monitored by the approved monitor. Respondent shall

1 make all records available for immediate inspection and copying on the premises by the monitor  
2 at all times during business hours and shall retain the records for the entire term of probation.

3 If Respondent fails to obtain approval of a monitor within 60 calendar days of the effective  
4 date of this Decision, Respondent shall receive a notification from the Board or its designee to  
5 cease the practice of medicine within three (3) calendar days after being so notified. Respondent  
6 shall cease the practice of medicine until a monitor is approved to provide monitoring  
7 responsibility.

8 The monitor shall submit a quarterly written report to the Board or its designee which  
9 includes an evaluation of Respondent's performance, indicating whether Respondent's practices  
10 are within the standards of practice of medicine, and whether Respondent is practicing medicine  
11 safely. It shall be the sole responsibility of Respondent to ensure that the monitor submits the  
12 quarterly written reports to the Board or its designee within 10 calendar days after the end of the  
13 preceding quarter.

14 If the monitor resigns or is no longer available, Respondent shall, within 5 calendar days of  
15 such resignation or unavailability, submit to the Board or its designee, for prior approval, the  
16 name and qualifications of a replacement monitor who will be assuming that responsibility within  
17 15 calendar days. If Respondent fails to obtain approval of a replacement monitor within 60  
18 calendar days of the resignation or unavailability of the monitor, Respondent shall receive a  
19 notification from the Board or its designee to cease the practice of medicine within three (3)  
20 calendar days after being so notified Respondent shall cease the practice of medicine until a  
21 replacement monitor is approved and assumes monitoring responsibility.

22 In lieu of a monitor, Respondent may participate in a professional enhancement program  
23 equivalent to the one offered by the Physician Assessment and Clinical Education Program at the  
24 University of California, San Diego School of Medicine, that includes, at minimum, quarterly  
25 chart review, semi-annual practice assessment, and semi-annual review of professional growth  
26 and education. Respondent shall participate in the professional enhancement program at  
27 Respondent's expense during the term of probation.

28

1           7.    NOTIFICATION. Within seven (7) days of the effective date of this Decision, the  
2 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the  
3 Chief Executive Officer at every hospital where privileges or membership are extended to  
4 Respondent, at any other facility where Respondent engages in the practice of medicine,  
5 including all physician and locum tenens registries or other similar agencies, and to the Chief  
6 Executive Officer at every insurance carrier which extends malpractice insurance coverage to  
7 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15  
8 calendar days. This condition shall apply to any change(s) in hospitals, other facilities or  
9 insurance carrier.

10           8.    SUPERVISION OF PHYSICIAN ASSISTANTS. During probation, Respondent is  
11 prohibited from supervising physician assistants.

12           9.    OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules  
13 governing the practice of medicine in California and remain in full compliance with any court  
14 ordered criminal probation, payments, and other orders.

15           10.   QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations  
16 under penalty of perjury on forms provided by the Board, stating whether there has been  
17 compliance with all the conditions of probation. Respondent shall submit quarterly declarations  
18 not later than 10 calendar days after the end of the preceding quarter.

19           11.   GENERAL PROBATION REQUIREMENTS.

20           Compliance with Probation Unit

21           Respondent shall comply with the Board's probation unit and all terms and conditions of  
22 this Decision.

23           Address Changes

24           Respondent shall, at all times, keep the Board informed of Respondent's business and  
25 residence addresses, email address (if available), and telephone number. Changes of such  
26 addresses shall be immediately communicated in writing to the Board or its designee. Under no  
27 circumstances shall a post office box serve as an address of record, except as allowed by Business  
28 and Professions Code section 2021(b).



1           Place of Practice

2           Respondent shall not engage in the practice of medicine in Respondent's or patient's place  
3 of residence, unless the patient resides in a skilled nursing facility or other similar licensed  
4 facility. This restriction shall not apply to Respondent's three existing patients who are home-  
5 bound and who are seen by Respondent in their homes, provided that the patients' records are  
6 maintained and are available in Respondent's office.

7           License Renewal

8           Respondent shall maintain a current and renewed California physician's and surgeon's  
9 license.

10          Travel or Residence Outside California

11          Respondent shall immediately inform the Board or its designee, in writing, of travel to any  
12 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty  
13 (30) calendar days.

14          In the event Respondent should leave the State of California to reside or to practice,  
15 Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of  
16 departure and return.

17          12. INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be  
18 available in person upon request for interviews either at Respondent's place of business or at the  
19 probation unit office, with or without prior notice throughout the term of probation.

20          13. NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or  
21 its designee in writing within 15 calendar days of any periods of non-practice lasting more than  
22 30 calendar days and within 15 calendar days of Respondent's return to practice. Non-practice is  
23 defined as any period of time Respondent is not practicing medicine in California as defined in  
24 Business and Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month  
25 in direct patient care, clinical activity or teaching, or other activity as approved by the Board. All  
26 time spent in an intensive training program which has been approved by the Board or its designee  
27 shall not be considered non-practice. Practicing medicine in another state of the United States or  
28 Federal jurisdiction while on probation with the medical licensing authority of that state or

1 jurisdiction shall not be considered non-practice. A Board-ordered suspension of practice shall  
2 not be considered as a period of non-practice.

3 In the event Respondent's period of non-practice while on probation exceeds 18 calendar  
4 months, Respondent shall successfully complete a clinical training program that meets the criteria  
5 of Condition 18 of the current version of the Board's "Manual of Model Disciplinary Orders and  
6 Disciplinary Guidelines" prior to resuming the practice of medicine.

7 Respondent's period of non-practice while on probation shall not exceed two (2) years.

8 Periods of non-practice will not apply to the reduction of the probationary term.

9 Periods of non-practice will relieve Respondent of the responsibility to comply with the  
10 probationary terms and conditions with the exception of this condition and the following terms  
11 and conditions of probation: Obey All Laws; and General Probation Requirements.

12 14. COMPLETION OF PROBATION. Respondent shall comply with all financial  
13 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the  
14 completion of probation. Upon successful completion of probation, Respondent's certificate shall  
15 be fully restored.

16 15. VIOLATION OF PROBATION. Failure to fully comply with any term or condition  
17 of probation is a violation of probation. If Respondent violates probation in any respect, the  
18 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and  
19 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,  
20 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have  
21 continuing jurisdiction until the matter is final, and the period of probation shall be extended until  
22 the matter is final.

23 16. LICENSE SURRENDER. Following the effective date of this Decision, if  
24 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy  
25 the terms and conditions of probation, Respondent may request to surrender his or her license.  
26 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in  
27 determining whether or not to grant the request, or to take any other action deemed appropriate  
28 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent


1 shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its  
2 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject  
3 to the terms and conditions of probation. If Respondent re-applies for a medical license, the  
4 application shall be treated as a petition for reinstatement of a revoked certificate.

5 17. PROBATION MONITORING COSTS. Respondent shall pay the costs associated  
6 with probation monitoring each and every year of probation, as designated by the Board, which  
7 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of  
8 California and delivered to the Board or its designee no later than January 31 of each calendar  
9 year.

10  
11 ACCEPTANCE

12 I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully  
13 discussed it with my attorney, Sharon Barclay Kime. I understand the stipulation and the effect it  
14 will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and  
15 Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the  
16 Decision and Order of the Medical Board of California.

17  
18 DATED: 10/6/16

  
ERIC DAVID GORDON, M.D.  
Respondent

19  
20  
21  
22 I have read and fully discussed with Respondent Eric David Gordon, M.D. the terms and  
23 conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order.  
24 I approve its form and content.

25  
26 DATED: 10.6.16

  
SHARON BARCLAY KIME  
Attorney for Respondent



**Exhibit A**

**Accusation No. 12-2012-227503**

1 KAMALA D. HARRIS  
Attorney General of California  
2 JOSE R. GUERRERO  
Supervising Deputy Attorney General  
3 LYNNE K. DOMBROWSKI  
Deputy Attorney General  
4 State Bar No. 128080  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 703-5578  
6 Facsimile: (415) 703-5480  
E-mail: Lynne.Dombrowski@doj.ca.gov  
7 *Attorneys for Complainant*

FILED  
STATE OF CALIFORNIA  
MEDICAL BOARD OF CALIFORNIA  
SACRAMENTO *Oct 16* 20 *15*  
BY *[Signature]* ANALYST

8  
9 **BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

10  
11 In the Matter of the Accusation Against:

Case No. 12-2012-227503

12 **Eric David Gordon, M.D.**  
3471 Regional Parkway  
13 Santa Rosa CA 95403

**ACCUSATION**

14 Physician's and Surgeon's Certificate  
15 No. G82342,

16 Respondent.

17  
18 Complainant alleges:

19 **PARTIES**

20 1. Kimberly Kirchmeyer (Complainant) brings this Accusation solely in her official  
21 capacity as the Executive Director of the Medical Board of California, Department of Consumer  
22 Affairs (Board).

23 2. On or about July 17, 1996, the Medical Board issued Physician's and Surgeon's  
24 Certificate Number G82342 to Eric David Gordon, M.D. (Respondent). The Physician's and  
25 Surgeon's Certificate was in full force and effect at all times relevant to the charges brought herein  
26 and will expire on January 31, 2016, unless renewed.

27 3. At all times relevant to the allegations herein, Respondent was the sole owner of  
28 Gordon Medical Associates.



1           “(g) The practice of medicine from this state into another state or country without meeting  
2 the legal requirements of that state or country for the practice of medicine. Section 2314 shall not  
3 apply to this subdivision. This subdivision shall become operative upon the implementation of the  
4 proposed registration program described in Section 2052.5.

5           “(h) The repeated failure by a certificate holder, in the absence of good cause, to attend and  
6 participate in an interview by the board. This subdivision shall only apply to a certificate holder  
7 who is the subject of an investigation by the board.”

8           7. Section 2242 of the Code states, in pertinent part:

9           “(a) Prescribing, dispensing, or furnishing dangerous drugs as defined in Section 4022  
10 without an appropriate prior examination and a medical indication, constitutes unprofessional  
11 conduct. . . .”

12           8. Section 2266 of the Code states: “The failure of a physician and surgeon to maintain  
13 adequate and accurate records relating to the provision of services to their patients constitutes  
14 unprofessional conduct.”

15           9. Section 725 of the Code states:

16           “(a) Repeated acts of clearly excessive prescribing, furnishing, dispensing, or administering  
17 of drugs or treatment, repeated acts of clearly excessive use of diagnostic procedures, or repeated  
18 acts of clearly excessive use of diagnostic or treatment facilities as determined by the standard of  
19 the community of licensees is unprofessional conduct for a physician and surgeon, dentist,  
20 podiatrist, psychologist, physical therapist, chiropractor, optometrist, speech-language pathologist,  
21 or audiologist.

22           “(b) Any person who engages in repeated acts of clearly excessive prescribing or  
23 administering of drugs or treatment is guilty of a misdemeanor and shall be punished by a fine of  
24 not less than one hundred dollars (\$100) nor more than six hundred dollars (\$600), or by  
25 imprisonment for a term of not less than 60 days nor more than 180 days, or by both that fine and  
26 imprisonment.

27       ///

28       ///



1           (c) A practitioner who has a medical basis for prescribing, furnishing, dispensing, or  
2 administering dangerous drugs or prescription controlled substances shall not be subject to  
3 disciplinary action or prosecution under this section.

4           (d) No physician and surgeon shall be subject to disciplinary action pursuant to this section  
5 for treating intractable pain in compliance with Section 2241.5."

#### 6                   **PERTINENT CONTROLLED SUBSTANCES/DANGEROUS DRUGS**

7           10. Abilify, a trade name for aripiprazole, is an anti-psychotic medication that is used to  
8 treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic  
9 depression). It may also be used together with other medications to treat major depressive  
10 disorder in adults. It is a dangerous drug as defined in Business and Professions Code section  
11 4022. Taking Abilify with other drugs that induce sleepiness can worsen the effect.

12           11. Actiq. See fentanyl.

13           12. Ambien, a trade name for zolpidem tartrate, is a non-benzodiazepine hypnotic of the  
14 imidazopyridine class. It is a Schedule IV controlled substance under Health and Safety Code  
15 section 11057(d)(32) and is a dangerous drug as defined in Business and Professions Code section  
16 4022. It is indicated for the short-term treatment of insomnia. It is a central nervous system  
17 (CNS) depressant and should be used cautiously in combination with other CNS depressants.  
18 Any CNS depressant could potentially enhance the CNS depressive effects of Ambien. It should  
19 be administered cautiously to patients exhibiting signs or symptoms of depression because of the  
20 risk of suicide. Because of the risk of habituation and dependence, individuals with a history of  
21 addiction to or abuse of drugs or alcohol should be carefully monitored while receiving Ambien.

22           13. Celexa, a trade name for citalopram, is an antidepressant in a group of drugs called a  
23 selective serotonin reuptake inhibitor ("SSRI") and it is used in the treatment of depression. It has  
24 primary CNS depressant effects and should be used with caution in combination with other  
25 centrally acting drugs. Celexa is a dangerous drug as defined in Business and Professions Code  
26 section 4022 of the Code.

27           14. Dilaudid, a trade name for hydromorphone hydrochloride, is a hydrogenated ketone of  
28 morphine and an opioid analgesic whose principal therapeutic use is for relief of pain. It is a

1 Schedule II controlled substance as defined by section 11055, subdivision (d) of the Health and  
2 Safety Code, and by Section 1308.12 (d) of Title 21 of the Code of Federal Regulations, and a  
3 dangerous drug as defined in Business and Professions Code section 4022. Psychic dependence,  
4 physical dependence, and tolerance may develop upon repeated administration of opioids;  
5 therefore, Dilaudid should be prescribed and administered with caution. Patients receiving other  
6 opioid analgesics, anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic  
7 antidepressants and other central nervous system depressants, including alcohol, may exhibit an  
8 additive central nervous system depression. When such combined therapy is contemplated, the  
9 use of one or both agents should be reduced.

10 15. Fentanyl is an opioid analgesic which can be administered by an injection, through a  
11 transdermal patch (known as Duragesic), as an oral lozenge (known as Actiq), or in tablet form  
12 (known as Fentora). It is a Schedule II controlled substance as defined by section 11055 of the  
13 Health and Safety Code and by Section 1308.12 of Title 21 of the Code of Federal Regulations,  
14 and is a dangerous drug as defined in Business and Professions Code section 4022. Fentanyl's  
15 primary effects are anesthesia and sedation. It is a strong opioid medication and is indicated only  
16 for treatment of chronic pain (such as that of malignancy) that cannot be managed by lesser means  
17 and that requires continuous opioid administration. Fentanyl presents a risk of serious or life-  
18 threatening hypoventilation. When patients are receiving fentanyl, the dosage of central nervous  
19 system depressant drugs should be reduced. Use of fentanyl together with other central nervous  
20 system depressants, including alcohol, can result in increased risk to the patient.

21 16. HCTZ or hydrochlorothiazide is a diuretic and antihypertensive. It is indicated as an  
22 adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis,  
23 corticosteroid and estrogen therapy, and various forms of renal dysfunction. It is also used in the  
24 management of hypertension, either as a sole therapeutic agent or to enhance the effectiveness of  
25 other antihypertensive drugs in the more severe forms of hypertension. It is a dangerous drug as  
26 defined in Business and Professions Code section 4022 of the Code.

27 ///

28 ///

1 17. Hydrocodone bitartrate with acetaminophen, which is known by the trade names  
2 Norco or Vicodin, is a semi-synthetic opioid analgesic. It is a Schedule II controlled substance as  
3 defined by section 11055, subdivision (b) of the Health and Safety Code, and is a Schedule II  
4 controlled substance as defined by section 1308.13 (e) of Title 21 of the Code of Federal  
5 Regulations<sup>1</sup>, and is a dangerous drug as defined in Business and Professions Code section 4022.

6 18. Ketamine is a short-acting dissociative injectable anesthetic that has some  
7 hallucinogenic effects. It induces a trance-like state while providing pain relief, sedation, and  
8 memory loss. It is a Schedule III controlled substance, as defined by section 11056 of the Health  
9 and Safety Code and is a dangerous drug as defined in Business and Professions Code section  
10 4022. Although primarily used in humans as an anesthetic, it may also be used for post-operative  
11 pain management or to treat major depression. In some limited cases it may be used to treat  
12 complex regional pain syndrome but its use in treating non-cancer chronic pain is considered to  
13 be controversial or experimental. Ketamine may increase the effects of other sedatives, such as  
14 alcohol, benzodiazepines, opioids, and barbiturates. It also has a high potential for abuse and for  
15 diversion.

16 19. Methadone hydrochloride is a synthetic opioid analgesic with multiple actions  
17 quantitatively similar to those of morphine. Methadone may be administered as an injectable  
18 liquid or in the form of a tablet, disc, or oral solution. It is a Schedule II controlled substance as  
19 defined by section 11055, subdivision (c) of the Health and Safety Code, and by Section 1308.12  
20 (c) of Title 21 of the Code of Federal Regulations, and is a dangerous drug as defined in Business  
21 and Professions Code section 4022. Methadone can produce drug dependence of the morphine  
22 type and, therefore, has the potential for being abused. Methadone should be used with caution  
23 and in reduced dosage in patients who are concurrently receiving other opioid analgesics.

24 ///

25 ///

26 \_\_\_\_\_  
27 <sup>1</sup> Effective 10/06/2014, all hydrocodone combination products were re-scheduled from  
28 Schedule III to Schedule II controlled substances by the Federal Drug Enforcement Agency  
("DEA"), section 1308.12 (b)(1)(vi) of Title 21 of the Code of Federal Regulations.

1           20. MS Contin, a trade name for morphine sulfate, is an opioid pain medication indicated  
2 for the management of pain severe enough to require daily, around-the-clock, long-term opioid  
3 treatment and for which alternative treatment options are inadequate. Morphine is a Schedule II  
4 controlled substance as defined by section 11055, subdivision (b) of the Health and Safety Code  
5 and is a dangerous drug as defined in Business and Professions Code section 4022. Morphine is  
6 a highly addictive drug which may rapidly cause physical and psychological dependence and, as a  
7 result, creates the potential for being abused, misused, and diverted.

8           21. Nuvigil, a trade name for armodafinil, is a prescription medication indicated to  
9 improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep  
10 apnea, narcolepsy, or shift work disorder. It is a dangerous drug as defined in Business and  
11 Professions Code section 4022.

12           22. Opana, a trade name for oxymorphone hydrochloride, is an opioid analgesic indicated  
13 for the relief of moderate to severe acute pain. Oxymorphone is a Schedule II controlled  
14 substance as defined by section 11055, subdivision (b)(1) of the Health and Safety Code, and is a  
15 dangerous drug as defined in Business and Professions Code section 4022. Because respiratory  
16 depression is the chief hazard, oxymorphone should be used with caution and started in a reduced  
17 dosage (1/3 to 1/2 of the usual dosage) in patients who are concurrently receiving other central  
18 nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines,  
19 tranquilizers, and alcohol.

20           23. OxyContin is a trade name for oxycodone hydrochloride controlled-release tablets.  
21 Oxycodone is a white odorless crystalline powder derived from an opium alkaloid. It is a pure  
22 agonist opioid whose principal therapeutic action is analgesia. Other therapeutic effects of  
23 oxycodone include anxiolysis, euphoria, and feelings of relaxation. OxyContin is a Schedule II  
24 controlled substance as defined by section 11055, subdivision (b)(1) of the Health and Safety  
25 Code, and by Section 1308.12 (b)(1) of Title 21 of the Code of Federal Regulations, and is a  
26 dangerous drug as defined in Business and Professions Code section 4022. Respiratory  
27 depression is the chief hazard from all opioid agonist preparations. OxyContin should be used  
28 with caution and started in a reduced dosage (1/3 to 1/2 of the usual dosage) in patients who are

1 concurrently receiving other central nervous system depressants including sedatives or hypnotics,  
2 general anesthetics, phenothiazines, other tranquilizers, and alcohol.

3 24. Soma, a trade name for carisoprodol, is a muscle-relaxant and sedative. It is a  
4 Schedule III controlled substance as defined by section 11056, subdivision (e) of the Health and  
5 Safety Code and by section 1308.13 (e) of Title 21 of the Code of Federal Regulations, and is a  
6 dangerous drug as defined in Business and Professions Code section 4022. Since the effects of  
7 carisoprodol and alcohol or carisoprodol and other central nervous system depressants or  
8 psychotropic drugs may be addictive, appropriate caution should be exercised with patients who  
9 take more than one of these agents simultaneously.

10 25. Tramadol is an opioid agonist of the morphine-type that is indicated for the  
11 management of moderate to severe pain. It is a Schedule IV controlled substance as defined by  
12 section 11057 of the Health and Safety Code and is a dangerous drug as defined in Business and  
13 Professions Code section 4022. Tramadol may be expected to have additive effects when used in  
14 conjunction with alcohol; other opioids, or illicit drugs that cause central nervous system  
15 depression.

16 26. Valium, a trade name for diazepam, is a psychotropic drug used for the management  
17 of anxiety disorders or for the short-term relief of the symptoms of anxiety. It is a Schedule IV  
18 controlled substance as defined by section 11057 of the Health and Safety Code and section  
19 1308.14 of Title 21 of the Code of Federal Regulations, and is a dangerous drug as defined in  
20 Business and Professions Code section 4022. Diazepam can produce psychological and physical  
21 dependence and it should be prescribed with caution particularly to addiction-prone individuals  
22 (such as drug addicts and alcoholics) because of the predisposition of such patients to habituation  
23 and dependence.

24 27. Xanax is a trade name for alprazolam tablets. Alprazolam is a psychotropic triazolo-  
25 analogue of the benzodiazepine class of central nervous system-active compounds. Xanax is used  
26 for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.  
27 It is a Schedule IV controlled substance as defined by section 11057, subdivision (d) of the Health  
28 and Safety Code, and by section 1308.14 (c) of Title 21 of the Code of Federal Regulations, and is

1 a dangerous drug as defined in Business and Professions Code section 4022. Xanax has a central  
2 nervous system depressant effect and patients should be cautioned about the simultaneous  
3 ingestion of alcohol and other CNS depressant drugs during treatment with Xanax.

4  
5 **FIRST CAUSE FOR DISCIPLINE**

6 **(Unprofessional Conduct: Gross Negligence, Incompetence, Prescribing Without**  
7 **Appropriate Exam and Medical Indication, Excessive Prescribing re Patient PJ)**

8 28. Respondent Eric David Gordon, M.D. is subject to disciplinary action under sections  
9 2234(b) and/or 2234(d) and/or 2242 and/or 725 in that Respondent's overall conduct, acts and/or  
10 omissions, with regard to patient PJ constitutes gross negligence and/or incompetence and/or  
11 prescribing without an appropriate prior examination and a medical indication and/or excessive  
12 prescribing, as more fully described herein below.

13 29. Respondent first saw patient PJ in about December 1997 when the patient, a then 42-  
14 year-old male, was referred to him for possible alternative therapy for Hepatitis C, and for  
15 osteopathic manipulation and trigger point injections. Patient PJ had been disabled because of a  
16 back injury in about 1989 while working as a plumber, for which the patient underwent four low-  
17 back surgeries between 1989 and 1992. At that time, patient PJ had another physician who was  
18 managing his chronic pain.

19 30. In about mid-2005, Respondent took over responsibility for patient PJ's pain  
20 management, after the patient's former pain management physician closed her practice.  
21 According to Respondent, at that time patient PJ was being prescribed #30 Actiq 1600 mcg.  
22 lozenges monthly, as needed for pain flares and #7 tablets daily of MS Contin 200 mg. and  
23 Respondent continued this prescribing regimen.

24 31. During the course of treatment, since at least November 2008, Respondent has  
25 reported providing treatment for the following medical diagnoses for patient PJ: Lyme disease,  
26 lumbago, sciatica, neuropathic pain, chronic fatigue syndrome, and generalized pain.

27 32. On or about August 4, 2010, another physician completed an initial pain consultation  
28 report for patient PJ that was initiated by the patient's primary care physician, a copy of which is

1 in Respondent's records. In that report, the current medications for patient PJ are listed as: 5-7  
2 tablets per day of MS Contin 200 mg.; Valium 10 mg. twice daily; Actiq (fentanyl lollypop) 600  
3 mcg. a month, and hydrochlorothorizide (HCTZ). The consulting physician's conclusion was that  
4 the patient was adequately managed with this treatment.

5 33. On or about September 27, 2010, Respondent issued a prescription by telephone for  
6 patient PJ for #180 Valium (Diazepam) 10 mg. with instructions for two tablets to be taken three  
7 times daily that included five refills.

8 34. On or about October 1, 2010, Respondent issued to patient PJ a prescription for the  
9 following controlled substances: #210 MS Contin 200 mg. with instructions for 3-4 tablets to be  
10 taken twice daily; #210 Valium 10 mg. with instructions for 3 tablets to be taken twice daily; and  
11 #7 Actiq 1600 mcg. lozenges to be taken as needed (prn).

12 35. On October 26, 2010, Respondent renewed the prescriptions for #210 MS Contin 200  
13 mg. and #7 Actiq 1600 mcg. lozenges.

14 36. Starting in or about February 2011, for a period of about four months, Respondent  
15 prescribed and dispensed a fentanyl nasal spray to patient PJ but there is inadequate  
16 documentation about the indication and dosing of this nasal spray. During those four months,  
17 from February 2011 through June 2011, Respondent also prescribed for patient PJ: Actiq, MS  
18 Contin, Diazepam, Opana ER 40 mg., and OxyContin.

19 37. For a visit on May 8, 2011, Respondent noted a Ketamine i.v. but the details of this  
20 treatment are not adequately documented in the patient's medical records.

21 38. On or about January 11, 2012, Respondent administered in his office to patient PJ  
22 5,000 mcg. of fentanyl intravenously over thirty minutes without any result. Respondent then  
23 administered intravenously another 10,000 mcg. of fentanyl over a period of one hour and the  
24 patient had some relief.

25 39. In or about February 2012, Respondent began to treat patient PJ for Lyme disease  
26 with i.v. antibiotics and an i.v. port was placed in the patient.

27 40. On or about March 7, 2012, patient PJ saw Respondent for an office visit and  
28 Respondent administered 10,000 mcg of i.v. fentanyl.

1           41. On or about March 14, 2012, a nurse's note indicates that patient PJ came to the  
2 office and was administered 10,000 mcg. (1.0 ml.) of i.v. fentanyl infused over thirty minutes.

3           42. Although not adequately documented in the medical records, sometime in March  
4 2012, Respondent gave patient PJ bags of fentanyl to take home and to self-administer via the i.v.  
5 port. A brief handwritten note dated March 16, 2012 from Respondent appears to instruct patient  
6 PJ to use no more than two 15, 000 mcg. bags a day, with each bag to be run over two hours.  
7 Respondent did not document in the patient's chart how many bags of i.v. fentanyl were  
8 dispensed and the medical indication for this prescribing.

9           43. On or about March 24, 2012, patient PJ saw Respondent for an office visit and  
10 Respondent administered intravenously 15,000 mcg. of fentanyl. Respondent noted that the  
11 patient reported that he was travelling to Dubai and to the Maldives for surfing.

12           44. A nurse's note dated March 27, 2012 documents that 1.5 cc. of fentanyl in a bag of  
13 Ringer's lactate was sent home with patient PJ, with no further information provided about the  
14 dispensing and instructions.

15           45. A nurse's note dated April 2, 2012 documents that three bags of Ringer's lactate with  
16 1500 mcg. each of fentanyl was made up by Respondent and given to patient PJ to take on  
17 vacation.

18           46. A note dated April 4, 2012 documents a telephone request from patient PJ to pick up  
19 two bags of fentanyl on April 10, 2012 because he was leaving on April 11, 2012 for vacation.  
20 There is no documentation in the patient's chart as to whether the requested fentanyl was  
21 dispensed.

22           47. Respondent was aware that patient PJ was a surfer and that he continued to surf until  
23 sometime in about 2014.

24           48. From August 20, 2012 to October 1, 2012, Patient PJ was hospitalized at Santa Rosa  
25 Memorial Hospital with diagnoses of an infected port-a-cath, discitis, osteomyelitis, depression  
26 with suicidality, obsessive compulsive disorder with possible PTSD, a history of Lyme disease  
27 and of hepatitis C, narcotic bowel, and a septic sacroiliac joint. A psychiatric diagnosis during  
28 this hospital admission also listed somatoform disorder as an Axis I diagnosis.



1           49. According to a CURES report, on October 31, 2012, patient PJ filled prescriptions  
2 from Respondent for #180 MS Contin 200 mg. and #200 Valium 10 mg. and on the next day  
3 filled a prescription for #6 Actiq lozenges.

4           50. On or about November 6, 2012, Respondent saw patient PJ for an office visit and  
5 noted that the patient had been in the hospital for seven weeks because of severe low back pain.  
6 Respondent's chart note mentions that the patient is to taper off the methadone, without any  
7 further explanation.

8           51. On or about November 26, 2012, Respondent and patient PJ signed an agreement  
9 form for Risk Evaluation and Mitigation Strategy (REMS) for Actiq, a Transmucosal Immediate  
10 Release Fentanyl (TIRF) medicine. The REMS agreement specifically states that the prescriber  
11 understands that the TIRF medicine is indicated only for the management of breakthrough pain in  
12 patients with cancer who are already receiving, and who are tolerant to, around-the-clock opioid  
13 therapy for their underlying persistent pain. Patient PJ was not being treated for cancer.

14           52. A nurse's note dated May 3, 2012 documents that patient PJ was given one 500 ml.  
15 bag Ringer's lactate with 60,000 mg. of fentanyl, with no additional information or explanation  
16 about the indication for this prescribing.

17           53. In March 2013, Patient PJ's i.v. catheter again became infected and the patient  
18 required hospitalization in Sebastopol for sepsis.

19           54. From at least January 1, 2012 through June 28, 2013, Respondent prescribed for  
20 patient PJ daily doses of about 1.2 grams of morphine equivalents and 60 mg. of diazepam.

21           55. On or about August 1, 2013, patient PJ saw Respondent for an office visit. The chart  
22 note indicates that the patient reported that he was now self-administering 60,000 mcg. of fentanyl  
23 in a 500 cc Ringer's lactate bag over a period of three hours. Although there is no documented  
24 medical indication and details about the prescribing and dosing instructions, it appears that patient  
25 PJ was also provided Dilaudid to take home for self-injection. Respondent's chart note for  
26 August 1, 2013 provides an incomplete list of what the patient was being prescribed.

27           56. In his interview with the Board's investigator, Respondent stated that it was his  
28 decision that patient PJ should administer all four bags of i.v. fentanyl at one time, so that the

1 patient would self-administer 60,000 mcg. of i.v. fentanyl on one night a week at home.

2 Respondent, however, did not adequately document in the patient's chart the indication for this  
3 change in dosing and when the change was made.

4 57. According to Respondent, since about 2013 through to at least June 2015, patient PJ  
5 has been self-administering about 60,000 mcg. of i.v. fentanyl once a week, in addition to his  
6 other prescribed medications that consist of: MS Contin 200 mg., three tablets taken twice daily,  
7 Dilaudid 50 mg. intramuscular (IM) injections every other day, on an "as needed basis," and  
8 Valium 10 mg. up to 7 tablets daily.

9 58. According to the CURES report, in 2014 Respondent prescribed the following  
10 controlled substances to patient PJ: #1380 tablets of morphine sulfate 200 mg. time-extended  
11 release; #30 tablets of morphine sulfate 60 mg. time-extended release; #30 tablets of morphine  
12 sulfate 30 mg. time-extended release; #2800 tablets of diazepam 10 mg.; #900 tablets of Opana 40  
13 mg. time-extended release; and an unknown quantity of fentanyl citrate powder provided on six  
14 separate dates.

15 59. Respondent's overall conduct, acts and/or omissions, with regard to patient PJ, as set  
16 forth in paragraphs 28 through 58 herein, constitutes unprofessional conduct through gross  
17 negligence and/or incompetence and/or prescribing without an appropriate prior examination and  
18 a medical indication and/or excessive prescribing, pursuant to Business and Professions Code  
19 Sections 2234 subdivisions (b) and/or (d) and/or section 2242 and/or section 725, and is therefore  
20 subject to disciplinary action. More specifically, Respondent is guilty of unprofessional conduct  
21 with regard to patient PJ as follows:

22 a. Respondent failed to document medical indications for his prescribing of  
23 controlled substances including, but not limited to, the high doses of opioids and the self-  
24 administered i.v. and IM opioids;

25 b. Respondent excessively prescribed controlled substances, particularly opioids, to  
26 patient PJ;

27 c. Respondent gave patient PJ fentanyl in extremely high doses to be administered  
28 intravenously at home, without proper monitoring;

1 d. Respondent prescribed controlled substances to patient PJ for chronic pain on an  
2 often irregular basis, with substantial breaks in the prescribing of controlled substances;

3 e. Respondent did not document in patient PJ's records that he discussed the risks  
4 and benefits of chronic opioid use with the patient, along with a discussion about other treatment  
5 modalities;

6 f. Respondent did not document any discussion with and education of patient PJ in  
7 the strict sterile protocols needed to be followed when using a permanent i.v. access line to  
8 administer medicines;

9 g. Respondent failed to adequately review the effectiveness of his treatments and  
10 continued to prescribe i.v. opioids to patient PJ, failing to consider the patient's two hospital  
11 admissions and the patient's very limited functional improvement with the treatment;

12 h. Respondent made no attempts to monitor the patient's chronic use of prescribed  
13 opioids;

14 i. Respondent failed to recognize and advise the patient of the risks involved with  
15 travelling outside the U.S. with high doses of controlled substances;

16 j. Respondent demonstrated a lack of knowledge in the proper use of opioids for the  
17 management of chronic pain;

18 k. Respondent's records are inadequate and incomplete and do not include sufficient  
19 information to explain medical decisions, documentation of appropriate physical examinations, a  
20 history of substance abuse, reports of functional status, accurate lists of current medications and  
21 current objective findings. The computer chart entries were often copied from previous visits,  
22 making it confusing and impossible to determine what information is current.

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 SECOND CAUSE FOR DISCIPLINE

2 **(Unprofessional Conduct: Gross Negligence, Incompetence, Prescribing Without**  
3 **Appropriate Exam and Medical Indication, Excessive Prescribing re Patient DF)**

4 60. Respondent is subject to disciplinary action under sections 2234(b) and/or 2234(d)  
5 and/or 2242 and/or 725 in that Respondent's overall conduct, acts and/or omissions, with regard  
6 to patient DF constitutes gross negligence and/or incompetence and/or prescribing without an  
7 appropriate prior examination and a medical indication and/or excessive prescribing, as more  
8 fully described herein below.

9 61. Respondent first saw Patient DF in January 2001 because the patient was interested in  
10 antibiotic therapy for her mixed connective tissue disease. When he first saw patient DF she was  
11 a forty-six-year old female who had been unable to work for about twenty years due to her pain  
12 and was homebound. Patient DF presented with diagnoses of mixed connective tissue disease  
13 with a scleroderma component, ulcer disease, scoliosis, chronic headaches, and severe  
14 musculoskeletal pains.

15 62. According to the CURES report, between October 30, 2009 and November 15, 2013,  
16 Respondent prescribed daily to patient DF up to 360 mg. of morphine, a 100 mcg/hr. fentanyl  
17 patch, 160 mg. methadone, along with large doses of orally absorbed fentanyl and  
18 benzodiazepines.

19 63. On or about February 11, 2011, Respondent saw patient DF for an office visit and  
20 documented that the patient reported that she is functioning better with the pain meds. The chart  
21 indicated that the patient was using #15 Actiq 1600 mcg. lozenges daily, in addition to MS  
22 Contin, methadone, and other prescribed medications. No physical examination was documented.

23 64. On or about January 5, 2012, patient DF was admitted to Santa Rosa Memorial  
24 Hospital with an "altered level of consciousness" after being found unresponsive in her home.

25 65. Respondent continued to prescribe high doses of opioids after the patient was released  
26 from the hospital.

27 66. On or about April 19, 2012, patient DF signed an agreement form for Risk  
28 Evaluation and Mitigation Strategy (REMS) for Actiq, a Transmucosal Immediate Release

1 Fentanyl (TIRF) medicine, but there is no corresponding signed agreement by Respondent in the  
2 patient's chart.

3 67. On or about May 7, 2013, Respondent saw patient DF for an office visit at which the  
4 patient reported still being in pain after taking 20 Actiq lozenges per day, in addition to her other  
5 opiate medications.

6 68. On or about April 29, 2014, Respondent and patient DF signed an agreement form  
7 for Risk Evaluation and Mitigation Strategy (REMS) for Actiq, a Transmucosal Immediate  
8 Release Fentanyl (TIRF) medicine. The REMS agreement specifically states that the prescriber  
9 understands that the TIRF medicine is indicated only for the management of breakthrough pain in  
10 patients with cancer who are already receiving, and who are tolerant to, around-the-clock opioid  
11 therapy for their underlying persistent pain. Patient DF was not being treated for cancer.

12 69. Patient DF's last visit to Respondent's offices was on May 21, 2014. The patient was  
13 seen by another provider and given trigger point injections. Respondent continued to be the  
14 physician prescribing patient DF's medications.

15 70. Patient DF died at her home on July 31, 2014. Respondent completed and signed the  
16 death certificate, listing the cause of death as severe esophagitis, mixed connective tissue disease,  
17 and severe scoliosis.

18 71. According to the CURES report for six-months in 2014 (January 21, 2014 through  
19 July 23, 2014), Respondent prescribed and patient DF obtained the following controlled  
20 substances: #4,704 fentanyl citrate oral transmucosal lozenges 1600 mcg.; #90 fentanyl  
21 transdermal 100 mcg/hr. patches; #1440 morphine sulfate 30 mg. time-extended release tablets;  
22 #900 morphine sulfate 15 mg. time-extended release tablets; #1500 methadone hydrochloride 10  
23 mg. tablets; #450 diazepam 10 mg. tablets; and, #150 zolpidem tartrate 5 mg. tablets.

24 72. Respondent's overall conduct, acts and/or omissions, with regard to patient DF, as set  
25 forth in paragraphs 60 through 71 herein, constitutes unprofessional conduct through gross  
26 negligence and/or incompetence and/or prescribing without an appropriate prior examination and  
27 a medical indication and/or excessive prescribing, pursuant to Business and Professions Code  
28 Sections 2234 subdivisions (b) and/or (d) and/or section 2242 and/or section 725, and is therefore

1 subject to disciplinary action. More specifically, Respondent is guilty of unprofessional conduct  
2 with regard to patient DF as follows:

3 a. Respondent failed to document medical indications for his prescribing of  
4 controlled substances;

5 b. Respondent excessively prescribed controlled substances, particularly opioids and  
6 benzodiazepines, to patient DF;

7 c. Respondent did not adequately document in the patient's chart appropriate physical  
8 examinations with objective findings;

9 d. Respondent did not appear to acknowledge and re-consider the effectiveness of his  
10 treatments after the patient was hospitalized for being in an altered state or upon evidence that the  
11 patient's pain and function showed no improvement with the high doses of controlled substances;

12 e. Respondent failed to document that he informed patient DF of the risks and  
13 benefits of the chronic use of opioids and benzodiazepines;

14 f. Respondent demonstrated a lack of knowledge in the proper use of opioids for the  
15 management of chronic pain;

16 g. Respondent's records are inadequate and incomplete and do not include sufficient  
17 information to explain medical decisions, documentation of appropriate physical examinations,  
18 reports of functional status, accurate lists of current medications and current objective findings.  
19 The computer chart entries were often copied from previous visits, making it confusing and  
20 impossible to determine what information is current;

21 h. Respondent did not obtain and document a substance abuse history for patient DF;

22 i. Respondent made no attempts to monitor the patient's chronic use of prescribed  
23 opioids;

24 j. Respondent completed and signed the death certificate without acknowledging that  
25 the prescribed opioids and benzodiazepines may have contributed to patient DF's death.

26 ///

27 ///

28 ///

1 THIRD CAUSE FOR DISCIPLINE

2 **(Unprofessional Conduct: Gross Negligence, Incompetence, Prescribing Without**  
3 **Appropriate Exam and Medical Indication, Excessive Prescribing re Patient JE)**

4 73. Respondent is subject to disciplinary action under sections 2234(b) and/or 2234(d)  
5 and/or 2242 and/or 725 in that Respondent's overall conduct, acts and/or omissions, with regard  
6 to patient JE constitutes gross negligence and/or incompetence and/or prescribing without an  
7 appropriate prior examination and a medical indication and/or excessive prescribing, as more  
8 fully described herein below.

9 74. Respondent first saw patient JE in about February 1998 when the patient, a then  
10 forty-one-year-old female, was referred to him by a pain specialist for osteopathic manipulations  
11 and trigger point injections. The patient was disabled due to low back pain and sciatica.  
12 According to Respondent, patient JE presented to him with a twenty-year history of alcohol abuse  
13 but stated that she had stopped drinking in February 1998.

14 75. In about 2005, Respondent took over managing patient JE's pain and the prescribing  
15 of opiates. According to Respondent, at that time Patient JE was generally taking 120-150 mg. of  
16 morphine or oxycodone four times daily along with "very high doses of methadone and  
17 extraordinarily high doses of Xanax."

18 76. Since at least January 2011, Respondent has also prescribed testosterone cream to  
19 patient JE without documenting the medical indication and findings to support this prescribing.

20 77. On or about January 7, 2011, Respondent saw patient JE and noted that the patient  
21 realized that she was using Xanax like alcohol and that it was time to taper the Xanax and to get  
22 psychiatric advice for her medications.

23 78. Respondent saw patient JE in his office four times in 2011, three times in 2012, and  
24 three times in 2013.

25 79. According to the prescribing records, between October 30, 2009 through at least  
26 November 15, 2013, Respondent had prescribed to patient JE up to 800 mg. of methadone per day  
27 while at the same time prescribing daily 36 mg. of alprazolam and 720 mg. of oxycodone.  
28

1           80. Respondent saw patient JE in his office seven times in 2014. She continued to get  
2 trigger point injections and osteopathic manipulation therapy (OMT).

3           81. On or about April 24, 2014, Respondent saw patient JE who reported that she was  
4 stable with her overall pain and that the medications allowed her to function, without providing  
5 further detail. Respondent's listed diagnoses for the visit included Lyme disease, sciatica, and  
6 lumbago/low back pain

7           82. During the course of his treatment and since at least January 2011, Respondent has  
8 not ordered an EKG or other tests to examine and assess the patient's complaints of back pain.

9           83. On or about June 24, 2014, Respondent recommended cannabis (marijuana for  
10 medical purposes) for patient JE without documenting the medical indication and without  
11 obtaining a substance abuse history.

12           84. On or about October 8, 2014, another physician saw and examined patient JE,  
13 observed that patient JE appeared over-sedated, and concluded that the patient was suffering  
14 many side effects from her current treatment of massive amounts of opiates. Respondent was  
15 provided a copy of the physician's report but did not change his prescribing to patient JE.

16           85. In a referral letter and summary dated October 20, 2014, Respondent reported that  
17 patient JE had a long history of myofascial pain and cervical and lumbar disc disease with long-  
18 standing right-sided sciatica. Respondent also reported that patient JE had a strong family history  
19 of depression and alcoholism and that she had been going to AA (Alcoholic's Anonymous) for  
20 over 25 years.

21           86. Respondent's records for patient JE include an email dated November 13, 2014 that  
22 stated that Respondent would no longer prescribe opioids to patient JE. There was no  
23 documented explanation for this decision in the patient's chart and it appears that Respondent  
24 issued prescriptions to patient JE in December 2014 for both methadone and oxycodone.

25           87. According to Respondent, he continues to treat patient JE but he is not her primary  
26 care physician.

27           88. According to the CURES report, in 2014 Respondent prescribed the following  
28 controlled substances to patient JE: #6480 tablets of methadone hydrochloride 10 mg.; #4140



1 tablets of oxycodone hydrochloride 30 mg.; #1320 tablets of alprazolam/Xanax 2 mg.; and an  
2 unspecified quantity of testosterone micronized powder on three separate dates. In addition,  
3 patient JE obtained from another physician in 2014: #1080 tablets of methadone hydrochloride 10  
4 mg. and #720 tablets of oxycodone hydrochloride 30 mg.

5 89. Respondent's overall conduct, acts and/or omissions, with regard to patient JE, as set  
6 forth in paragraphs 73 through 88 herein, constitutes unprofessional conduct through gross  
7 negligence and/or incompetence and/or prescribing without an appropriate prior examination and  
8 a medical indication and/or excessive prescribing, pursuant to Business and Professions Code  
9 Sections 2234 subdivisions (b) and/or (d) and/or section 2242 and/or section 725, and is therefore  
10 subject to disciplinary action. More specifically, Respondent is guilty of unprofessional conduct  
11 with regard to patient JE as follows:

12 a. Respondent failed to document medical indications for his prescribing of  
13 controlled substances;

14 b. Respondent excessively prescribed controlled substances, particularly opioids, to  
15 patient JE;

16 c. Respondent did not appear to consider the patient's substance abuse history in his  
17 clinical decision making;

18 d. Respondent did not appear to acknowledge and re-consider the effectiveness of his  
19 treatments upon evidence that the patient's function did not improve with the high doses of  
20 controlled substances and/or that the patient was suffering many side effects from the opioids;

21 e. Respondent failed to document that he informed patient JE of the risks and  
22 benefits of the chronic use of opioids;

23 f. Respondent made no attempts to monitor the patient's chronic use of prescribed  
24 opioids;

25 g. Respondent demonstrated a lack of knowledge in the proper use of opioids for the  
26 management of chronic pain;

27 h. Respondent's records are inadequate and incomplete and do not include sufficient  
28 information to explain medical decisions, documentation of appropriate physical examinations,

1 reports of functional status, accurate lists of current medications and current objective findings.  
2 The computer chart entries were often copied from previous visits, making it confusing and  
3 impossible to determine what information is current.  
4

5 **FOURTH CAUSE FOR DISCIPLINE**

6 **(Unprofessional Conduct: Gross Negligence, Incompetence, Prescribing Without**  
7 **Appropriate Exam and Medical Indication, Excessive Prescribing re Patient VT)**

8 90. Respondent Eric David Gordon, M.D. is subject to disciplinary action under sections  
9 2234(b) and/or 2234(d) and/or 2242 and/or 725 in that Respondent's overall conduct, acts and/or  
10 omissions, with regard to patient VT constitutes gross negligence and/or incompetence and/or  
11 prescribing without an appropriate prior examination and a medical indication and/or excessive  
12 prescribing, as more fully described herein below.

13 91. Respondent first saw patient VT in October 2004 when the patient was referred to him  
14 for assistance with mercury detoxification. Patient VT, a then 43-year-old female, presented with  
15 a history of muscle tension and migraine headaches. Patient VT had a primary care physician.

16 92. Respondent's records for patient VT indicate diagnoses of fibromyalgia, migraine,  
17 chronic fatigue, sleep apnea, tinnitus, hyperacusis, cervalgia, and common variable  
18 immunodeficiency.

19 93. Between October 2009 and June 2013, Respondent prescribed to patient VT the  
20 following controlled substances: hydrocodone 10/325 mg. four times daily; tramadol 50 mg. twice  
21 daily; Soma 350 mg. three times daily; Ambien 10 mg., up to two tablets per day; topical  
22 ketamine; and Nuvigil. Respondent also provided patient VT with prolotherapy, trigger point  
23 injections, chiropractic treatments, and complementary medicine treatments (ozone,  
24 detoxifications, chi machine, and non-allopathic medications.)

25 94. On or about April 25, 2011, Respondent noted in the office visit that ketamine nasal  
26 spray would be tried to treat the patient's hyperacusis but there is no documentation of what was  
27 dispensed to the patient and the dosing instructions. Respondent also prescribed Ambien in two  
28 different strengths (10 mg. and 12.4 mg) without documenting a recognized medical indication.

1           95. During the course of his treatment of patient VT, Respondent never documented the  
2 frequency and duration of the patient's migraine headaches.

3           96. In or about November 2011, patient VT had a consultation with a specialist about  
4 headaches and that physician recommended that the patient limit the use of Norco to no more than  
5 10 days a month. Respondent received a copy of the report but did not change his prescribing of  
6 Norco to patient VT, which was about #90 tablets monthly.

7           97. According to the CURES report, in 2014 Respondent prescribed the following  
8 controlled substances to patient VT: #990 Ambien 10 mg. tablets; #900 tramadol hydrochloride  
9 50 mg. tablets; #1440 carisoprodol (Soma) 350 mg. tablets; #1680 Norco 325 mg./10 mg. tablets;  
10 an unknown quantity of #37 ketamine hydrochloride powder; and #90 Nuvigil 150 mg.

11           98. According to Respondent, he continues to treat patient VT but he is not her primary  
12 care physician.

13           99. Respondent's overall conduct, acts and/or omissions, with regard to patient VT, as set  
14 forth in paragraphs 90 through 98 herein, constitutes unprofessional conduct through gross  
15 negligence and/or incompetence and/or prescribing without an appropriate prior examination and  
16 a medical indication and/or excessive prescribing, pursuant to Business and Professions Code  
17 Sections 2234 subdivisions (b) and/or (d) and/or section 2242 and/or section 725, and is therefore  
18 subject to disciplinary action. More specifically, Respondent is guilty of unprofessional conduct  
19 with regard to patient VT as follows:

20           a. Respondent prescribed excessively high doses of Ambien to patient VT without  
21 documenting a recognized medical indication;

22           b. Respondent did not document informing patient VT of the risks and benefits of  
23 the chronic use of opioids along with other treatment modalities;

24           c. Respondent made no attempts to monitor the patient's chronic use of prescribed  
25 opioids;

26           d. Respondent did not obtain and document a substance abuse history for patient VT;

27           e. Respondent's records are inadequate and incomplete and do not include sufficient  
28 information to explain medical decisions, documentation of appropriate physical examinations,

1 reports of functional status, accurate lists of current medications and current objective findings.  
2 The computer chart entries were often copied from previous visits, making it confusing and  
3 impossible to determine what information is current.

4  
5 **FIFTH CAUSE FOR DISCIPLINE**

6 **(Unprofessional Conduct: Inadequate and/or Inaccurate Medical Records re Patients**  
7 **PJ, DF, JE, and VT)**

8 100. Respondent is subject to disciplinary action for unprofessional conduct under section  
9 2266 for failure to maintain adequate and accurate records relating to the provision of services to  
10 patient PJ and/or patient DF and/or patient JE and/or patient VT, as alleged in paragraphs 28  
11 through 99, which are incorporated herein by reference as if fully set forth.

12  
13 **SIXTH CAUSE FOR DISCIPLINE**

14 **(Unprofessional Conduct: Repeated Negligent Acts re Patients PJ, DF, JE, and/or VT)**

15 101. In the alternative, Respondent is subject to disciplinary action for unprofessional  
16 conduct, jointly and severally, under section 2234(c) for repeated negligent acts with regard to his  
17 acts and/or omissions with regards to patient PJ and/or patient DF and/or patient JE and/or patient  
18 VT, as alleged in paragraphs 28 through 99, which are incorporated herein by reference as if fully  
19 set forth.

20 **PRAYER**

21 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,  
22 and that following the hearing, the Medical Board of California issue a decision:

23 1. Revoking or suspending Physician's and Surgeon's Certificate Number G82342,  
24 issued to Eric David Gordon, M.D.;

25 2. Revoking, suspending or denying approval of Eric David Gordon, M.D.'s authority to  
26 supervise physician assistants, pursuant to section 3527 of the Code;


27 ///

28 ///

1           3.    Ordering Eric David Gordon, M.D., if placed on probation, to pay the Board the costs  
2 of probation monitoring; and,

3           4.    Taking such other and further action as deemed necessary and proper.

4  
5 DATED: October 16, 2015

  
KIMBERLY KIRCHMEYER  
Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*

6  
7  
8  
9  
10 SF2015402390

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## Exhibit B

1 XAVIER BECERRA  
Attorney General of California  
2 JANE ZACK SIMON  
Supervising Deputy Attorney General  
3 LYNNE K. DOMBROWSKI  
Deputy Attorney General  
4 State Bar No. 128080  
455 Golden Gate Avenue, Suite 11000  
5 San Francisco, CA 94102-7004  
Telephone: (415) 510-3439  
6 Facsimile: (415) 703-5480  
E-mail: Lynne.Dombrowski@doj.ca.gov  
7 *Attorneys for Complainant*

8 **BEFORE THE**  
**MEDICAL QUALITY HEARING PANEL**  
9 **OF THE OFFICE OF ADMINISTRATIVE HEARINGS**  
10 **STATE OF CALIFORNIA**

11 In the Matter of the Petition for Interim Order  
of Suspension Against:

12  
13 **ERIC DAVID GORDON, M.D.**  
3471 Regional Parkway  
14 Santa Rosa, CA 95403-1202

15 Physician's and Surgeon's Certificate  
16 No. G82342

17 Respondent.

Case No. 800-2018-039973

OAH No. 2018 030375

**STIPULATION FOR INTERIM ORDER  
RESTRICTING MEDICAL PRACTICE;  
INTERIM ORDER**

18  
19 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
20 entitled proceeding as follows:

21 1. Petitioner Kimberly Kirchmeyer (Petitioner) is the Executive Director of the Medical  
22 Board of California (Board). She brought this action solely in her official capacity and is  
23 represented in this matter by and through her attorney Xavier Becerra, Attorney General of the  
24 State of California, by Lynne K. Dombrowski, Deputy Attorney General.

25 2. On or about July 17, 1996, the Medical Board of California issued Physician's and  
26 Surgeon's Certificate No. G82342 to Eric David Gordon, M.D. (Respondent). The Physician's  
27 and Surgeon's Certificate is current and it will expire on January 31, 2020, unless renewed.

28 Respondent's certificate is presently subject to disciplinary action through a probation of three

1 years with special terms and conditions, which began on December 16, 2016 pursuant to the  
2 Medical Board's Decision and Order dated November 18, 2016 in Case No. 12-2012-227503.

3 3. Respondent Eric David Gordon M.D. is represented in this matter by attorney Marvin  
4 Firestone, MD, JD of Marvin Firestone, MD, JD & Associates, LLP, 1700 South El Camino Real,  
5 Suite 204, San Mateo, CA 94402.

6 4. The parties hereby stipulate and agree that an interim order restricting Respondent's  
7 license to practice medicine may be issued pursuant to Government Code section 11529.  
8 Respondent willingly enters into this Stipulation with a full understanding of its terms and  
9 restrictions.

10 4. Respondent is aware of his rights under California Government Code section 11529  
11 to a formal hearing on the allegations in the Petition for Interim Order of Suspension, which  
12 include the right to be represented by counsel at his own expense, to have a record made of the  
13 proceedings, to present affidavits and other documentary evidence, and to present oral argument.  
14 Respondent hereby knowingly and voluntarily waives each of these rights.

15 5. Respondent hereby stipulates and agrees that the Medical Quality Hearing Panel of  
16 the Office of Administrative Hearings has jurisdiction in this matter and, without further  
17 proceedings, may issue an interim order that restricts Respondent's practice by the following  
18 terms and conditions. Respondent Dr. Gordon hereby agrees to be immediately restrained and  
19 prohibited as follows:

20 (a) Respondent Dr. Gordon shall not possess, prescribe, dispense, furnish,  
21 administer, or otherwise distribute any controlled substance;

22 (b) Upon demand, Respondent Dr. Gordon shall surrender to the Medical Board, or  
23 its designated representative, for safekeeping all Drug Enforcement Administration (DEA) Drug  
24 Order Forms, and any and all DEA permits, pending further order in this matter.

25 (c) The Interim Order shall become effective at 5:00 p.m. on March 30, 2018, to  
26 allow Respondent Dr. Gordon time to make the proper arrangements regarding the transfer of  
27 patient care.

28




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

(d) The probation terms and conditions currently in effect pursuant to the Medical Board's Decision and Order in Case No. 12-2012-227503 shall remain in full force and effect.

(e) The Interim Order shall remain in force and effect until such time as the Medical Board of California issues and adopts a final decision on the Accusation to be filed in this matter pursuant to the provisions of Government Code sections 11503 and 11505.

6. The parties further understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulation for Interim Order Restricting Medical Practice; Interim Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals and that this stipulation may be signed in counterpart.

I have carefully read this Stipulation for Interim Order Restricting Medical Practice; Interim Order and I have fully discussed the terms and implications of this stipulation with my attorney, Marvin Firestone, M.D., J.D. Pursuant to the terms of this stipulation, I agree to the entry of an Interim Order Restricting Medical Practice under Government Code section 11529. I understand the effect that this stipulation will have on my Physician's and Surgeon's Certificate No. C82342.

DATED: 3/23/18   
ERIC DAVID GORDON, M.D.  
Respondent

I have read and fully discussed the terms of this Stipulation with my client, Respondent Eric David Gordon, M.D, and I approve its form and content.

DATED: 3/26/18   
MARVIN FIRESTONE, MD, JD  
Attorney for Respondent

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

IT IS SO STIPULATED.

DATED: 03/26/2018

XAVIER BECERRA  
Attorney General of California  
JANE ZACK SIMON  
Supervising Deputy Attorney General


Lynne K. Dombrowski  
LYNNE K. DOMBROWSKI  
Deputy Attorney General  
Attorneys for Petitioner



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

7. This Order shall be deemed served upon Respondent upon service by electronic mail and by overnight delivery to Respondent's attorney, Marvin Firestone, M.D., J.D. The Order shall also be served by regular mail upon Respondent at his address of record with the Board.

DATED: March 26, 2018

  
ADMINISTRATIVE LAW JUDGE  
MEDICAL QUALITY HEARING PANEL  
DAVID BENJAMIN

SF2018400077